Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution
Menu

Contact Us
If you have any questions or feedback please contact us.

Peter A Forsberg

TitleAssociate Professor
InstitutionUniversity of Colorado Denver - Anschutz Medical Campus
DepartmentSOM-MED
Phone720/848-9307

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Keller AL, Sherbenou DW, Forsberg PA, Mark TM. Harnessing the T Cell to Treat Multiple Myeloma: Dawn of a New Therapeutic Paradigm. Front Oncol. 2022; 12:925818. PMID: 35814431.
      View in: PubMed
    2. Forsberg PA, Rossi AC, Boyer A, Pearse RN, Pekle KA, Jayabalan D, Lakritz S, Flicker K, Ribadeneyra D, Liotta B, Ely S, Boussi L, Allan JN, Coleman M, Niesvizky R, Mark TM. Carfilzomib and dexamethasone induction with lenalidomide, clarithromycin and dexamethasone consolidation and lenalidomide maintenance for newly diagnosed multiple myeloma. Am J Hematol. 2021 12 01; 96(12):1554-1562. PMID: 34424561.
      View in: PubMed
    3. Lindholm KE, Forsberg PA, Ewalt MD. Ibrutinib response in cutaneous transformed lymphoplasmacytic lymphoma. EJHaem. 2021 Aug; 2(3):565-568. PMID: 35844727.
      View in: PubMed
    4. Sherbenou D, Stalker M, Forsberg P, Mark TM. Sustained Response to Selinexor-Based Therapy for Triple-Class Refractory Multiple Myeloma with Early Relapse After Allogeneic Stem Cell Transplantation. Clin Lymphoma Myeloma Leuk. 2021 07; 21(7):e630-e634. PMID: 33863694.
      View in: PubMed
    5. Walker ZJ, Idler BM, Davis LN, Stevens BM, VanWyngarden MJ, Ohlstrom D, Bearrows SC, Hammes A, Smith CA, Jordan CT, Mark TM, Forsberg PA, Sherbenou DW. Exploiting Protein Translation Dependence in Multiple Myeloma with Omacetaxine-Based Therapy. Clin Cancer Res. 2021 02 01; 27(3):819-830. PMID: 33109736.
      View in: PubMed
    6. Sharma P, Purev E, Haverkos B, Pollyea DA, Cherry E, Kamdar M, Mark T, Forsberg P, Sherbenou D, Hammes A, Rabinovitch R, Smith CA, Gutman JA. Adult cord blood transplant results in comparable overall survival and improved GRFS vs matched related transplant. Blood Adv. 2020 05 26; 4(10):2227-2235. PMID: 32442301.
      View in: PubMed
    7. Walker ZJ, VanWyngarden MJ, Stevens BM, Abbott D, Hammes A, Langouët-Astrie C, Smith CA, Palmer BE, Forsberg PA, Mark TM, Jordan CT, Sherbenou DW. Measurement of ex vivo resistance to proteasome inhibitors, IMiDs, and daratumumab during multiple myeloma progression. Blood Adv. 2020 04 28; 4(8):1628-1639. PMID: 32311014.
      View in: PubMed
    8. Mark TM, Forsberg PA, Rossi AC, Pearse RN, Pekle KA, Perry A, Boyer A, Tegnestam L, Jayabalan D, Coleman M, Niesvizky R. Phase 2 study of clarithromycin, pomalidomide, and dexamethasone in relapsed or refractory multiple myeloma. Blood Adv. 2019 02 26; 3(4):603-611. PMID: 30792190.
      View in: PubMed
    9. Forsberg PA, Rossi AC, Boyer A, Tegnestam L, Pearse RN, Perry A, Pekle KA, Jayabalan D, Ely S, Boussi L, Sherbenou DW, Williams C, Allan JN, Coleman M, Niesvizky R, Mark TM. Phase II study of carfilzomib and dexamethasone therapy for newly diagnosed multiple myeloma. Am J Hematol. 2019 05; 94(5):539-545. PMID: 30740766.
      View in: PubMed
    10. Forsberg PA, Hammes A, Abbott D, Sherbenou DW, Rossi A, Jayabalan D, Niesvizky R, Mark TM, Ely S. Cellular proliferation by multiplex immunohistochemistry identifies aggressive disease behavior in relapsed multiple myeloma. Leuk Lymphoma. 2019 08; 60(8):2085-2087. PMID: 30632821.
      View in: PubMed
    11. Ely S, Forsberg P, Ouansafi I, Rossi A, Modin A, Pearse R, Pekle K, Perry A, Coleman M, Jayabalan D, Di Liberto M, Chen-Kiang S, Niesvizky R, Mark TM. Cellular Proliferation by Multiplex Immunohistochemistry Identifies High-Risk Multiple Myeloma in Newly Diagnosed, Treatment-Naive Patients. Clin Lymphoma Myeloma Leuk. 2017 Dec; 17(12):825-833. PMID: 29051077.
      View in: PubMed
    12. Sherbenou DW, Mark TM, Forsberg P. Monoclonal Antibodies in Multiple Myeloma: A New Wave of the Future. Clin Lymphoma Myeloma Leuk. 2017 09; 17(9):545-554. PMID: 28734795.
      View in: PubMed
    13. Mark TM, Guarneri D, Forsberg P, Rossi A, Pearse R, Perry A, Pekle K, Tegnestam L, Greenberg J, Shore T, Gergis U, Mayer S, Van Besien K, Ely S, Jayabalan D, Sherbenou D, Coleman M, Niesvizky R. A Phase I Trial of High-Dose Lenalidomide and Melphalan as Conditioning for Autologous Stem Cell Transplantation in Relapsed or Refractory Multiple Myeloma. Biol Blood Marrow Transplant. 2017 Jun; 23(6):930-937. PMID: 28285081.
      View in: PubMed
    14. Forsberg P, DeSancho MT. Role of novel anticoagulants for patients with mechanical heart valves. Curr Atheroscler Rep. 2014 Nov; 16(11):448. PMID: 25172513.
      View in: PubMed
    15. Chapin J, Shore T, Forsberg P, Desman G, Van Besien K, Laurence J. Hematopoietic transplant-associated thrombotic microangiopathy: case report and review of diagnosis and treatments. Clin Adv Hematol Oncol. 2014 Sep; 12(9):565-73. PMID: 25654478.
      View in: PubMed
    16. Forsberg PA, Mark TM. Pomalidomide in the treatment of relapsed multiple myeloma. Future Oncol. 2013 Jul; 9(7):939-48. PMID: 23837756.
      View in: PubMed
    Forsberg's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    See all (78) concept(s)
    _
    Co-Authors Expand Description
    See all (9) people
    _
    Similar People Expand Description
    See all (60) people
    _
    Same Department Expand Description
    Search Department

    Copyright © 2023 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)